Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Accumulated Expenses (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Accumulated Expenses for 14 consecutive years, with $4.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 68.53% year-over-year to $4.4 million, compared with a TTM value of $4.4 million through Dec 2025, down 68.53%, and an annual FY2025 reading of $4.4 million, down 68.53% over the prior year.
  • Accumulated Expenses was $4.4 million for Q4 2025 at Karyopharm Therapeutics, down from $66.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $66.3 million in Q3 2025 and bottomed at $4.4 million in Q4 2025.
  • Average Accumulated Expenses over 5 years is $45.5 million, with a median of $54.0 million recorded in 2021.
  • The sharpest move saw Accumulated Expenses soared 38.86% in 2021, then crashed 68.53% in 2025.
  • Year by year, Accumulated Expenses stood at $19.7 million in 2021, then decreased by 0.31% to $19.6 million in 2022, then plummeted by 31.44% to $13.5 million in 2023, then grew by 3.43% to $13.9 million in 2024, then crashed by 68.53% to $4.4 million in 2025.
  • Business Quant data shows Accumulated Expenses for KPTI at $4.4 million in Q4 2025, $66.3 million in Q3 2025, and $62.9 million in Q2 2025.